ReviewVaccines2025
Porcine Reproductive and Respiratory Syndrome Virus: Challenges and Advances in Vaccine Development.
Review in Vaccines, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Pathogenicity and virulence of PRRSV: From regulated cell death reprogramming landscape and immune subversion to precision vaccinology.Virulence · 2026Review
- A Lipid Nanoparticle-Formulated GP5-mRNA Vaccine Induces PRRSV-Specific Humoral and Cellular Immune Responses in BALB/c Mice.Veterinary sciences · 2026Article
- Cross-Species Reactivity and Differential Anti-PRRSV Activities of CD163 SRCR4/SRCR5 Monoclonal Antibodies.Veterinary sciences · 2026Article
- Integrated Single-Cell and TCR Profiling Reveals Protection-Associated CD8Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Porcine reproductive and respiratory syndrome virus antagonizes the host restriction factor SHFL to sustain viral programmed ribosomal frameshifting and replication.Journal of virology · 2026Article
- Glycyrrhizic Acid-Modified Gold Nanoparticles Show Inhibitory Activity Against PRRSV and SARS-CoV-2 Pseudovirus In Vitro.Viruses · 2026Article
- Verapamil HCl demonstrates antiviral activity against porcine reproductive and respiratory syndrome virus by regulating CaMicrobiology spectrum · 2026Article
- Small-molecule PS10 inhibits PRRSV replication by targeting HSP90 and multiple viral non-structural proteins.Journal of virology · 2026Article
- A Systematic Review and Meta-Analysis on the Global Seroprevalence of Porcine Reproductive and Respiratory Virus (PRRSV) in Pigs and Wild Boars: A Widespread and Impactful Swine Virus.Veterinary sciences · 2026Review
- In vitro evaluation of Limosilactobacillus and Enterococcus isolates for inhibitory activity against porcine reproductive and respiratory syndrome virus.Archives of microbiology · 2026Article
- Reverse genetics approach for arteriviruses using circular polymerase extension reaction.Access microbiology · 2026Article
- Development of a novel duplex crystal digital PCR for the detection of PRRSV-1 and PRRSV-2.Frontiers in cellular and infection microbiology · 2026Article
- Article
- Epidemiological Review of Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) in Japan: From Discovery and Spread to Economic Losses and Future Prospects.Veterinary sciences · 2025Review
- Efficacy of an intranasally administered live attenuated PRRSV-2 vaccine against challenge with a highly virulent PRRSV-1 strain.Frontiers in veterinary science · 2025Article
- Epidemiology and genetic characterization of porcine reproductive and respiratory syndrome virus in Fujian Province, China, from 2023 to 2024.Frontiers in veterinary science · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Persistent infection of porcine reproductive and respiratory syndrome virus (PRRSV) significantly hampers both the quantity and quality of pork production in China. Although PRRSV is widely prevalent worldwide, the absence of effective vaccines has made it one of the major pathogens threatening the sustainable development of the global swine industry. Vaccination remains one of the most effective measures for controlling pathogen infections. However, the continuous genetic recombination and mutation of PRRSV demand more comprehensive strategies to address emerging threats, while ensuring the efficacy and safety of vaccines. This review provides an overview of the latest advances in PRRSV vaccine research, highlighting the importance of understanding the unique strengths and limitations of various vaccines in developing effective therapeutic approaches and vaccination strategies. Moreover, the development of adjuvants and antiviral drugs as adjuncts to combat PRRSV infection offers significant potential for enhancing disease control efforts. With the advancement of technologies such as proteolysis-targeting chimera (PROTAC) and mRNA, new avenues for controlling PRRSV and other pathogens are emerging, offering considerable hope. Ultimately, the goal of these vaccine developments is to alleviate the impact of PRRSV on animal health and the profitability of the swine industry.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.